![WebsitePageHeader-[]-Carter](https://curesanfilippofoundation.org/wp-content/uploads/2022/02/WebsitePageHeader-Carter.jpg)
Page last updated: September 8, 2026
For web accessibility options: Click/tap the floating blue icon on the right.
Clinical trials and studies are where the rubber meets the road, scientifically.
Clinical trials for Sanfilippo are the crucial step of determining whether earlier research (basic and translational) shows the same therapeutic benefits in people.
Participation in observational studies and research surveys are opportunities to contribute to scientists’ understand of symptoms of Sanfilippo and how things change over time for the children. Participation also helps researchers develop new and improved outcome measures and more.
Current Clinical Studies in Sanfilippo Syndrome
DOWNLOAD: All Sanfilippo Clinical Trials At-A-Glance
Cure Sanfilippo Foundation has created a consolidated, printable, and easy-to-share document that details all current clinical trials for Sanfilippo Syndrome. Download it by clicking the button below. The information is for your reference and is not meant to replace consultation with your doctor or other sources. Information and changes to clinical trial offerings occur frequently and may not be reflected fully.
Contact us at Contact@CureSanfilippoFoundation.org if you would like more information about any of these clinical trial or other earlier-stage research underway.
We do our best to keep the list of clinical trials and studies for Sanfilippo up to date. However, we recommend periodically searching for “Sanfilippo” or “MPS III” on ClinicalTrials.gov and ClinicalTrialsRegister.eu in order for you to have the most-current information and to stay on top of newly-emerging clinical trial listings. Additionally, check back frequently with staff at Cure Sanfilippo Foundation and our website, as well as your medical team, for updates.
Individual Listings for Current Clinical Trials for Sanfilippo Syndrome
Clinical Trials: Gene Therapy
EGT-101 Gene Therapy | MPS IIIA | Phase I-II | Esteve
Update: April 2021 This Phase 1/2 trial has now fully enrolled and is not accepting additional patients.We are hopeful that a Phase 3 trial will be initiated in the future but no timeline is currently available.Trial Information EGT-101 is Esteve's potential...
SNG-101 Gene Therapy | MPS IIIB | Phase I-II | Sangrail
Page last updated: May 5, 2026 Page reviewed by: Dr. Cara O'Neill, FAAP For web accessibility options: Click/tap the floating blue icon on the right.Summary Information The SNG-101 (formerly ABO-101) gene therapy uses an adeno-associated virus serotype 9 carrying the...
UX111 Gene Therapy | MPS IIIA | Phase I-II-III | Ultragenyx
Page last updated: July 17, 2026 Page reviewed by: Dr. Cara O'Neill, FAAP For web accessibility options: Click/tap the floating blue icon on the right.Summary Information The UX111 (formerly ABO-102) Gene Therapy uses a self-complementary adeno-associated virus...
Clincal Trials: Enzyme Replacement
Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB | MPS IIIB | Expanded Access | Spruce Bio
Page last updated: September 8, 2026 For web accessibility options: Click/tap the floating blue icon on the right.Clinical Trial Summary This is an intermediate-size patient population Early Access Program (EAP) providing access to intracerebroventricular (ICV)...
JR-446 Enzyme Replacement | MPS IIIB | Phase I-II | MEDIPAL/JCR
Page last updated: August 13, 2026 Page reviewed by: Dr. Cara O'Neill, FAAP For web accessibility options: Click/tap the floating blue icon on the right.Trial Summary “JR-446 is a novel drug developed based on the J-Brain Cargo technology, which has been clinically...
GC1130A Enzyme Replacement | MPS IIIA | Phase I | GC Biopharma
Page last updated: July 29, 2025 Page reviewed by: Dr. Cara O'Neill, FAAP For web accessibility options: Click/tap the floating blue icon on the right.Clinical Trial Summary Study: Phase 1 Study of GC1130A in Pediatric Patients With Sanfilippo Syndrome Type A (MPS...
DNL126 Enzyme Replacement | MPS IIIA | Phase I-II | Denali
Page last updated: February 6, 2026 Page reviewed by: Dr. Cara O'Neill, FAAP For web accessibility options: Click/tap the floating blue icon on the right.Clinical Trial Summary Study: “A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability,...
JR-441 Enzyme Replacement | MPS IIIA | Phase I-II | JCR
Page last updated: August 30, 2024 For web accessibility options: Click/tap the floating blue icon on the right. Trial Information Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA A Phase I/ II, open-label, randomized, 2-arm study, designed...
TA-ERT Enzyme Replacement | MPS IIIB | Phase I-II | Spruce Biosciences
Page last updated: September 9, 2026 For web accessibility options: Click/tap the floating blue icon on the right.Clinical Trial Summary Study: Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidosis Type IIIB (TrAnsform) Trial Listing: Read...
Clincal Trials: Stem Cell Therapy
Gene-Modified Autologous Hematopoietic Stem Cells | MPS IIIA | Phase I-II | Orchard Therapeutics
Page last updated: July 23, 2026 For web accessibility options: Click/tap the floating blue icon on the right.Trial Information This study is the first in-human clinical trial to explore the safety, tolerability, and clinical efficacy of ex vivo gene...
Clincal Trials: Other Treatment Strategies
Study of Cannabidiol in Sanfilippo Syndrome | MPS IIIA, IIIB, IIIC, and IIID | Phase II-III | Lundquist
Page last updated: March 31, 2026 Page reviewed by: Dr. Cara O'Neill, FAAP For web accessibility options: Click/tap the floating blue icon on the right.Clinical Trial Summary Study: “Study of Epidiolex (cannabidiol) in Sanfilippo Syndrome” Trial Listing: Read this...
Ambroxol Hydrochloride | MPS IIIA, IIIB, IIIC, IIID | Phase II-III | Lysosomal & Rare Disorders Research & Treatment Center
Page last updated: August 20, 2025 For web accessibility options: Click/tap the floating blue icon on the right.Trial Information Study title: An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol...
Clincal Trials: Observational Studies/Natural History Studies
Natural History to Assess Disease in Patients With MPS IIIC (C-RARE) | MPS IIIC | Observational Study | UT Southwestern Children’s Medical Center
Page last updated: July 17, 2026 For web accessibility options: Click/tap the floating blue icon on the right.Study Summary This is a REMOTE prospective observational study of participants with Sanfilippo Syndrome Type IIIC (MPS IIIC). Patients’ functional abilities...
Natural History Study of Participants With Sanfilippo Syndrome Type IIIC | MPS IIIC | Observational Study | Hospices Civils De Lyon
Page last updated: May 14, 2026 For web accessibility options: Click/tap the floating blue icon on the right.Study Summary In this multi-center, natural history study of subjects with Sanfilippo syndrome type C (MPS IIIC), patients will be monitored over a 2-year...
A Natural History Study of Patients With Sanfilippo Disease(s) (MPS3) | MPS IIIA, IIIB, IIIC, IIID | Observational Study | Lysosomal Center
Page last updated: January 31, 2023 For web accessibility options: Click/tap the floating blue icon on the right.Trial Information Lysosomal and Rare Disorders Research and Treatment Center, Inc. is conducting a natural history study of patients with Sanfilippo...
Past Clinical Trials
SOB-103 Enzyme Replacement | MPS IIIA | Phase I-II | Sobi
Update: April 27, 2021 Last year Sobi decided to halt development of this ERT program. The patients enrolled in the trial were provided access to drug for the full 2 years of the planned trial period. All patients have now completed the trial and transitioned off of...
Open-label Study of Anakinra | MPS IIIA, IIIB, IIIC, IIID | Phase II-III | The Lundquist Institute
Page last updated: June 21, 2024 Page reviewed by: Dr. Cara O'Neill, FAAP For web accessibility options: Click/tap the floating blue icon on the right.Clinical Trial Summary Study: “Open-label Study of Anakinra in MPS III" (ClinicalTrials.gov ID: NCT04018755) Study...
LYS-SAF302 Gene Therapy | MPS IIIA | Phase II-III | Lysogene
Page last updated: February 19, 2024 Page reviewed by: Dr. Cara O'Neill, FAAP For web accessibility options: Click/tap the floating blue icon on the right.Summary Study: “Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated...
Past Observational Studies/Natural History Studies
A Natural History Study of Sanfilippo Syndrome Type D (MPSIIID) | MPS IIID | Observational Study | Phoenix Nest
Page last updated: August 11, 2025 For web accessibility options: Click/tap the floating blue icon on the right.Trial Information Phoenix Nest and National Institute of Neurological Disorders and Stroke (NINDS) are conducting a observational research study, which can...
Natural History of Biomarkers & Clinical Outcomes | MPS IIIA | Observational Study | Sanguine/Denali
Trial Information Denali Therapeutics is conducting a observational research study, which can also be called a natural history study, into Sanfilippo syndrome Type A (MPS IIIA). The purpose of the research study is to collect blood and behavioral information from...
More Research on Sanfilippo
Beyond clinical trials, there is basic and translational research (earlier-stage research) exploring multiple therapies about how to address the systemic impact and symptoms of Sanfilippo in order to improve the quality of life for a child with Sanfilippo. Learn more about the entire ecosystem of Sanfilippo research, as well as current scientific news.
Research Funded by Cure Sanfilippo Foundation
Cure Sanfilippo Foundation architects and funds promising research to accelerate discovery of a treatment or cure for Sanfilippo. Explore the research funded by the Foundation.
Learn more about the Foundation
We are the nation’s largest 501(c)3 nonprofit dedicated to advocating and funding research to bring about treatments and/or a cure for Sanfilippo Syndrome. Cure Sanfilippo has funded research grants around the world which has helped clinical trials get underway, treating children with Sanfilippo Syndrome. The Foundation creates and explores innovative and breakthrough research to ensure multiple promising paths are being explored in the effort to save children and better their quality of life.

Dr. Cara O’Neill, Chief Science Officer for the Foundation, meeting with researchers conducting important work regarding Sanfilippo in their lab to talk about progress and ideas.

Parents of children with Sanfilippo meeting to contribute to the Foundation’s work to create materials to help scientists and regulators better include the patient and caregiver perspective in research.



